Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
Consultancy firm Oliver Wyman said in a report this week that European banks will face a delayed credit impact from the coronavirus pandemic if they fail to unwind emergency government support measures properly. -
Chinese biotechnology company Brii Biosciences has raised HK$2.48bn ($319.7m) from its Hong Kong IPO, after pricing the deal at the top of the marketed range.
-
South Korea’s busy IPO market is continuing to pump out deals, with the latest listings coming from Kakao Pay and Covid-19 test maker SD Biosensor. But issuers still have to be realistic, as Krafton found out when it shot for, but missed, the country’s largest ever IPO.
-
Kantonsspital Graubünden sold a successful debut bond on Thursday, surprising bankers as it slipped in before the summer break.
-
Bulgarian animal healthcare company Huvepharma has become the latest casualty in an IPO market oversaturated with supply.
-
The EBRD’s central and eastern European heartland faces tough challenges as it seeks to regain its economic footing after being laid low by the outbreak of the Covid-19 pandemic
